Title:
FUSION PROTEIN OF SERUM ALBUMIN AND BIOACTIVE PROTEIN
Document Type and Number:
WIPO Patent Application WO/2024/080305
Kind Code:
A1
Abstract:
According to one embodiment of the present invention, a bioactive protein that usually has a low expression level and/or low activity when expressed as a recombinant protein using a host cell such as a CHO cell can be expressed in the form of a fusion protein with serum albumin (SA) to allow efficient production as a highly active recombinant protein. The fusion protein may be one in which the bioactive protein is bonded to either the amino terminal side or the carboxyl terminal side of the SA. The fusion protein can also form a conjugate with a ligand or an antibody.
Inventors:
TAKAHASHI KENICHI (JP)
ZOLOTARYOV FYODOR N (JP)
HORIUCHI MARIA (JP)
MIYAUCHI KAZUKI (JP)
ZOLOTARYOV FYODOR N (JP)
HORIUCHI MARIA (JP)
MIYAUCHI KAZUKI (JP)
Application Number:
PCT/JP2023/036886
Publication Date:
April 18, 2024
Filing Date:
October 11, 2023
Export Citation:
Assignee:
JAPAN CHEM RES (JP)
International Classes:
C12N15/62; C07K14/54; C07K14/765; C07K19/00; C12N5/10; C12N15/13; C12N15/14; C12N15/24; C12N15/63; C12P21/02
Domestic Patent References:
| WO2022067334A1 | 2022-03-31 | |||
| WO2017043569A1 | 2017-03-16 |
Foreign References:
| JP2009515819A | 2009-04-16 |
Other References:
EIJI YUBA: "Suppression of Rheumatoid Arthritis by Enhanced Lymph Node Trafficking of Engineered Interleukinâ10 in Murine Models", ARTHRITIS & RHEUMATOLOGY, JOHN WILEY & SONS, INC., US, vol. 73, no. 5, 1 May 2021 (2021-05-01), US , pages 769 - 778, XP093159301, ISSN: 2326-5191, DOI: 10.1002/art.41585
Attorney, Agent or Firm:
YAMAMOTO, Yoshiki et al. (JP)
Download PDF: